Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223645 | 1.00 | MAOA (0.46) | MAOAMAOBALDH1A1MAPTADRB2 | |
| SCHEMBL1764304 | 0.89 | MAOA (0.46) | MAOAMAOBALDH1A1MAPTADRB2 | |
| SCHEMBL560342 | 0.87 | MAOB (0.48) | MAOAMAOBADRB2CREBBPADRB1 | |
| SCHEMBL29498303 | 0.87 | MAOB (0.48) | MAOAMAOBADRB2CREBBPADRB1 | |
| SCHEMBL564845 | 0.85 | MAOA (0.46) | MAOAMAOBADRB2CREBBPADRB1 | |
| SCHEMBL19327165 | 0.84 | GYS1 (0.42) | MAOAMAOBALDH1A1MAPTADRB2 | |
| SCHEMBL18227270 | 0.84 | MAOA (0.41) | MAOAMAOBALDH1A1MAPTADRB2 | |
| SCHEMBL28944096 | 0.82 | ADRB2 (0.43) | MAOAMAOBADRB2CREBBPADRB1 | |
| SCHEMBL18239882 | 0.81 | MAPT (0.43) | MAOAMAOBALDH1A1MAPTADRB2 | |
| SCHEMBL563580 | 0.80 | ADRB2 (0.42) | MAOAMAOBADRB2CREBBPADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115678936-A | Method for selectively synthesizing chiral alcohol and epoxy compound | 广东东阳光药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-107108502-A | having beta2Biphenyl derivatives with receptor agonism and M receptor antagonistic activity and application thereof in medicine | 四川海思科制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016180349-A1 | BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| EP-1789405-B1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| EP-1809236-B1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20120034275-A1 | POWDER FORMULATIONS FOR INHALATION, COMPRISING ENANTIOMERICALLY PURE BETA AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8034809-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090137578-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, PROCESS FOR THE MANUFACTURE THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
| WO-2007104772-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| EP-1809236-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1789405-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-30 | — | — | EP | disclosed |
| US-7220742-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | LUSTENBERGER PHILIPP | 2007-02-01 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110359-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111005-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | ADRB1, ADRB2, ADRA1B | MAOA 376/4885MAOB 206/4885ALDH1A1 2339/4885 |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | ADRB1, ADRA1B, ADRA2B | MAOA 313/4885MAOB 182/4885ALDH1A1 2222/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | MAOA 984/4885MAOB 1198/4885ALDH1A1 2341/4885 |
| US-20090137578-A1 | ENANTIOMERICALLY PURE BETA AGONISTS, PROCESS FOR THE MANUFACTURE THEREOF AND USE THEREOF AS MEDICAMENTS | ADRB1, ADRB2, ADRA1D | MAOA 528/4885MAOB 536/4885ALDH1A1 1138/4885 |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | MAOA 600/4885MAOB 611/4885ALDH1A1 1255/4885 |
| US-20120034275-A1 | POWDER FORMULATIONS FOR INHALATION, COMPRISING ENANTIOMERICALLY PURE BETA AGONISTS | ADRB1, ADRB2, ADRB3 | MAOA 699/4885MAOB 630/4885ALDH1A1 765/4885 |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | ADRB1, ADRB2, ADRB3 | MAOA 699/4885MAOB 630/4885ALDH1A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.